Aspirin for primary prevention of vascular disease in people with diabetes.

Aspirin for primary prevention of vascular disease in people with diabetes.

Podrobná bibliografie
Hlavní autoři:	Haynes, R, Bowman, L, Armitage, J
Médium:	Journal article
Jazyk:	English
Vydáno:	2009

Podobné jednotky

Aspirin in the primary prevention of vascular disease Reply
Autor: Baigent, C, a další
Vydáno: (2009)

Aspirin in the primary prevention of vascular disease Reply
Autor: Baigent, C, a další
Vydáno: (2009)

Effects of aspirin for primary prevention in persons with diabetes mellitus
Autor: Bowman, L, a další
Vydáno: (2018)

Aspirin for primary prevention of cardiovascular disease in diabetes
Autor: Ying Xing, a další
Vydáno: (2019-07-01)

Which people should take aspirin for primary prevention of cardiovascular disease?
Autor: Lozano R, a další
Vydáno: (2015-07-01)

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
Autor: Bowman, L, a další
Vydáno: (2017)

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial
Autor: Parish, S, a další
Vydáno: (2022)

ASCEND-Eye: effects of aspirin on diabetic retinopathy
Autor: Sammons, E, a další
Vydáno: (2024)

Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
Autor: Algra Ale, a další
Vydáno: (2000-11-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
Autor: Mant, J, a další
Vydáno: (2021)

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Autor: Price, H, a další
Vydáno: (2009)

Role of aspirin in primary prevention of cardiovascular disease
Autor: Patrono, C, a další
Vydáno: (2019)

Aspirin overutilization for the primary prevention of cardiovascular disease
Autor: VanWormer JJ, a další
Vydáno: (2014-12-01)

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Autor: Baigent, C, a další
Vydáno: (2009)

Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients)
Autor: Hamzah Khan, a další
Vydáno: (2021-12-01)

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Autor: Hennekens, C, a další
Vydáno: (1989)

Should aspirin be used for primary prevention?
Autor: Mohit Bhagwati, a další
Vydáno: (2019-01-01)

Application of aspirin in the primary prevention of stroke
Autor: Zhao YANG, a další
Vydáno: (2015-02-01)

Aspirin for primary prevention: Is this the end of the road?
Autor: Aayush Kumar Singal, a další
Vydáno: (2019-03-01)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
Autor: Yinong Chen, a další
Vydáno: (2021-09-01)

US population qualifying for aspirin use for primary prevention of cardiovascular disease
Autor: Athena L. Huang, a další
Vydáno: (2024-06-01)

US POPULATION QUALIFYING FOR ASPIRIN USE FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:
Autor: Athena L. Huang, MD, a další
Vydáno: (2023-09-01)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
Autor: Fernández-de-Bobadilla Jaime, a další
Vydáno: (2007-10-01)

Aspirin use for primary prevention in elderly patients
Autor: Pierfranco Terrosu
Vydáno: (2016-06-01)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
Autor: Sergio Coccheri
Vydáno: (2017-04-01)

Aspirin for prevention of cancer and cardiovascular disease.
Autor: Rose, P, a další
Vydáno: (2011)

Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a)
Autor: Eleni Giannopoulou, a další
Vydáno: (2024-12-01)

PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN DIABETES MELLITUS: THE ROLE OF ASPIRIN
Autor: L. A. Strizhakov
Vydáno: (2012-04-01)

Prevention. Aspirin in primary prevention--good news and bad news.
Autor: Hennekens, C, a další
Vydáno: (2012)

Prevention: Aspirin in primary prevention-good news and bad news
Autor: Hennekens, C, a další
Vydáno: (2012)

The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention
Autor: Soo Hyun Kang, a další
Vydáno: (2025-01-01)

Aspirin for the Primary Prevention of Vascular Ischemic Events: An Updated Systematic Review and Meta-analysis to Support Shared Decision-Making
Autor: Chloë Laferrière, MD, a další
Vydáno: (2023-12-01)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
Autor: Hamzah Khan, a další
Vydáno: (2022-08-01)

Aspirin for primary prevention of cardiovaascular events: what are the evidances?
Autor: Yenny Yenny
Vydáno: (2019-08-01)

6 voices in 10 minutes: Aspirin in primary prevention
Autor: Carlos Buso
Vydáno: (2020-11-01)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
Autor: Xie W, a další
Vydáno: (2019-09-01)

Analysis of the Dilemma Involving Statins and Aspirin as Primary Prevention Alternatives in Cardiovascular Disease
Autor: Henry Sutanto
Vydáno: (2017-10-01)

Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis.
Autor: Inge Stegeman, a další
Vydáno: (2015-01-01)

CLINICAL SIGNIFICANCE OF ASPIRIN RESISTANCE IN PATIENTS WITH CARDIO-VASCULAR DISEASES
Autor: P. J. Dovgalevsky, a další
Vydáno: (2016-01-01)

ASPIRIN FOR PRIMARY PREVENTION IN HIGH-RISK TYPE 2 DIABETES: INSIGHTS FROM THE ACCORD TRIAL
Autor: Juliana H. Namutebi, MD, MS
Vydáno: (2024-09-01)